United Therapeutics UTHR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.17B-0.4% | $3.18B+1.7% | $3.13B+1.6% | $3.08B+2.8% | $2.99B+4.1% | ||
| $425.3M+10.6% | $384.4M+7.7% | $356.9M+5.2% | $339.1M+3.0% | $329.3M+6.3% | ||
| $2.74B-1.9% | $2.8B+1.0% | $2.77B+1.2% | $2.74B+2.8% | $2.66B+3.8% | ||
| 86.6%-1.3pp | 87.9%-0.7pp | 88.6%-0.4pp | 89%0.0pp | 89%-0.2pp | ||
| $539.2M-2.0% | $550M+1.0% | $544.3M+4.6% | $520.3M-1.1% | $525.9M+9.3% | ||
| $769.8M+1.9% | $755.8M+3.0% | $733.7M-4.8% | $770.3M+4.7% | $735.4M+3.6% | ||
| $1.73B+2.6% | $1.69B+3.4% | $1.63B+0.3% | $1.63B+2.5% | $1.59B+6.0% | ||
| $1.44B-3.8% | $1.49B-0.1% | $1.49B+3.1% | $1.45B+3.2% | $1.4B+1.9% | ||
| 45.3%-1.6pp | 46.9%-0.8pp | 47.7%+0.7pp | 47%+0.2pp | 46.9%-1.0pp | ||
| $16.4M-15.9% | $19.5M-19.8% | $24.3M-22.6% | $31.4M-12.0% | $35.7M-16.8% | ||
| $182.7M-4.8% | $192M-3.1% | $198.1M-1.7% | $201.5M+2.6% | $196.4M-1.4% | ||
| $173.2M-21.8% | $221.4M+28.1% | $172.9M+2.4% | $168.9M+5.3% | $160.4M-1.0% | ||
| $1.61B-6.1% | $1.71B+2.9% | $1.67B+3.1% | $1.62B+3.4% | $1.56B+1.6% | ||
| $321.3M-15.3% | $379.2M-3.9% | $394.7M+5.3% | $374.9M+6.1% | $353.2M+2.7% | ||
| $1.29B-3.5% | $1.33B+5.0% | $1.27B+2.4% | $1.24B+2.6% | $1.21B+1.3% | ||
| 40.6%-1.3pp | 41.9%+1.3pp | 40.7%+0.3pp | 40.4%-0.1pp | 40.4%-1.1pp | ||
| $27.08-2.9% | $27.89+5.6% | $26.41+3.0% | $25.64+2.2% | $25.08+1.9% | ||
| $29.28-2.9% | $30.14+5.8% | $28.48+2.9% | $27.68+2.2% | $27.08+2.5% | ||
| 190.7M-0.7% | 192.1M-0.3% | 192.7M-0.6% | 193.8M+0.4% | 193M-0.6% | ||
| 176.7M-0.8% | 178.1M-0.5% | 179M-0.4% | 179.8M+0.4% | 179.1M-1.2% | ||
| $6.9M-85.9% | $48.9M— | —— | —— | —— | ||
| $3.17B-0.4% | $3.18B+1.7% | $3.13B+1.6% | $3.08B+2.8% | $2.99B+4.1% | ||
| $1.52B-3.4% | $1.58B+0.1% | $1.58B+3.2% | $1.53B+3.2% | $1.48B+2.2% | ||
| 48.1%-1.5pp | 49.6%-0.8pp | 50.4%+0.7pp | 49.6%+0.2pp | 49.5%-0.9pp | ||
| $1.44B-3.8% | $1.49B-0.1% | $1.49B+3.1% | $1.45B+3.2% | $1.4B+1.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is United Therapeutics's revenue?
- United Therapeutics (UTHR) generated $3.2B in revenue over the trailing twelve months, up 5.9% year over year.
- Is United Therapeutics profitable?
- United Therapeutics reported $1.3B in net income over the trailing twelve months, a 40.6% net margin.
- What are United Therapeutics's profit margins?
- Gross margin is 86.6% and operating margin is 45.3%, with a 40.6% net margin.
- What is United Therapeutics's earnings per share?
- United Therapeutics's diluted EPS over the trailing twelve months is $27.08.
- Where does United Therapeutics's income statement data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
